Abbott Laboratories reported strong Q2 earnings that exceeded expectations, driving its stock up 14%. The company also raised its full-year 2026 guidance, signaling confidence in future growth. Key business areas like diagnostics and electrophysiology showed solid performance, and Abbott returned $2.1 billion to shareholders in the quarter. Despite mixed technical signals, the company’s profitability, dividend yield, and pipeline progress support a Hold rating post-earnings.
UK GDP grew 0.8% over three months, surpassing forecasts and showing resilience despite geopolitical tensions and energy price pressures. The FTSE 100 opened lower as investors digested takeover deals including Rotork's £4.1bn acquisition by ABB and ...
Abbott posted a 13% increase in reported sales and 4.8% comparable sales growth for Q2 2026, with GAAP diluted EPS at $0.53 and adjusted EPS at $1.31. The company reaffirmed its full-year 2026 sales growth guidance of 6.5% to 7.5% and raised its adju...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
